At present, there are no specific targeted drugs for the treatment of pneumonia (COVID-19) caused by the novel coronavirus (SARS-CoV-2). Interferon, lopinavir/ritonavir, ribavirin, chloroquine phosphate were chosen as off-label use, and remdesivir was chosen as compassionate use. This paper reviewed the behavior of the two medication response to the new major infectious disease.

Objective To compare the difference of volatile organic compounds (VOCs) in the urine of diabetic patients comorbid with or without depression. Methods Patients with type 2 diabetes who met the diagnostic criteria of prevention and treatment guidelines and were treated in inpatient department of Sixth People’s Hospital South Campus, Shanghai Jiaotong University, from November 2019 to November 2020 were included in the study. Depression screening was performed using PHQ9 scale. According to the scores, the patients were divided into two groups: diabetic patient group and diabetic patient comorbidity depression group. The morning urine was collected and VOCs in urine were detected using a miniature gas tester. Results A total of 161 patients with diabetes mellitus, including 141 patients in the diabetic group and 20 patients in the diabetic comorbidity depression group. The results indicated that the sensitivity, specificity and accuracy of the method are 80%, 98% and 92.8% respectively. There were differences in urine volatile organic compounds between the two groups. Conclusions Compared with diabetic patients, the composition of volatile organic compounds in urine may change after diabetic comorbidity depression, which can provide experimental reference for early clinical diagnosis of depression.